N-(3H-benzimidazol-5-yl)-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxo-1-pyridinyl]-3-methylbutanamide
C25H22ClN5O3 — CID 151965861
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-(3H-benzimidazol-5-yl)-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxo-1-pyridinyl]-3-methylbutanamide
N-(3H-benzimidazol-5-yl)-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxo-1-pyridinyl]-3-methylbutanamide (PubChem CID 151965861) has the molecular formula C25H22ClN5O3 and a molecular weight of 475.94 g/mol. Its IUPAC name is N-(3H-benzimidazol-5-yl)-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxo-1-pyridinyl]-3-methylbutanamide.
Molecular Properties
| Compound Name | N-(3H-benzimidazol-5-yl)-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxo-1-pyridinyl]-3-methylbutanamide |
|---|---|
| PubChem CID | 151965861 |
| Molecular Formula | C25H22ClN5O3 |
| Molecular Weight | 475.94 g/mol |
| Exact Mass | 475.14 |
| IUPAC Name | N-(3H-benzimidazol-5-yl)-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxo-1-pyridinyl]-3-methylbutanamide |
| SMILES | COc1cn(C(C(=O)Nc2ccc3nc[nH]c3c2)C(C)C)c(=O)cc1-c1cc(Cl)ccc1C#N |
| InChI | InChI=1S/C25H22ClN5O3/c1-14(2)24(25(33)30-17-6-7-20-21(9-17)29-13-28-20)31-12-22(34-3)19(10-23(31)32)18-8-16(26)5-4-15(18)11-27/h4-10,12-14,24H,1-3H3,(H,28,29)(H,30,33) |
| InChIKey | TZQIWHWWHNABKT-UHFFFAOYSA-N |
| XLogP | 4.76 |
| TPSA | 112.80 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 475.94 |
| LogP ≤ 5 | 4.76 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 151965861 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.